What is ACONW's health score?

Aclarion, Inc. (ACONW) has a TradeApes health score of 36 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ACONW's estimated fair value?

Based on our 5-year discounted cash flow model, Aclarion, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ACONW undervalued or overvalued?

Our model currently rates ACONW as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

1 free score card remaining

Aclarion, Inc. (ACONW)

Healthcare Inconclusive inconclusive weak

Updated: 2026-07-18

TradeApes Score

Financial Strength

40 Weak

Operating Trend

40 Weak

Relative Value

15 Stressed

Capital Allocation

30 Weak

Risk Management

80 Strong

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Historically expensive — EV/EBITDA in top 20% of its 5-year range

Unlock Full Report →

Industry Related Stocks

AGILENT TECHNOLOGIES, INC. (A) ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) AUTOSCOPE TECHNOLOGIES CORP (AATC) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.